James J. Burns & Company’s Akebia Therapeutics AKBA Stock Holding History

James J. Burns & Company’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.1K	Hold	11,448	–	–	﹤0.01%	163
2026 Q1	$15.9K	Hold	11,448	–	–	﹤0.01%	155
2025 Q4	$18.4K	Sell	11,448 -300	-3%	-$628	﹤0.01%	161
2025 Q3	$32.1K	Hold	11,748	–	–	﹤0.01%	159
2025 Q2	$42.8K	Hold	11,748	–	–	0.01%	155
2025 Q1	$22.6K	Sell	11,748 -754	-6%	-$1.54K	﹤0.01%	143
2024 Q4	$24K	Sell	12,502 -3,100	-20%	-$5.38K	﹤0.01%	147
2024 Q3	$21K	Hold	15,602	–	–	﹤0.01%	141
2024 Q2	$16K	Hold	15,602	–	–	﹤0.01%	128
2024 Q1	$25K	Sell	15,602 -2,800	-15%	-$4.48K	0.01%	85
2023 Q4	$23K	Sell	18,402 -6,140	-25%	-$6.26K	0.01%	120
2023 Q3	$28K	Sell	24,542 -600	-2%	-$771	0.01%	104
2023 Q2	$23K	Hold	25,142	–	–	0.01%	113
2023 Q1	$14K	Hold	25,142	–	–	﹤0.01%	112
2022 Q4	$15K	Hold	25,142	–	–	0.01%	79
2022 Q3	$8K	Buy	+25,142	New	+$9.87K	﹤0.01%	79

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

James J. Burns & Company's AKBA Position: Q2 2026 in Review

James J. Burns & Company held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 11,448 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #163.

James J. Burns & Company first reported a position in AKBA in Q3 2022 and has held it in 16 quarters since. The position peaked at $42.8K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

James J. Burns & Company held 11,448 shares of Akebia Therapeutics worth $13.1K as of Q2 2026.
James J. Burns & Company left its Akebia Therapeutics share count unchanged in Q2 2026.
Akebia Therapeutics made up ﹤0.01% of James J. Burns & Company's portfolio in Q2 2026, its #163 holding.
James J. Burns & Company first reported a position in Akebia Therapeutics in Q3 2022 and has held it in 16 quarters since.
James J. Burns & Company's Akebia Therapeutics position peaked at $42.8K in Q2 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on James J. Burns & Company's 13F filing for Q2 2026, filed 6 Aug 2026.